Durata Therapeutics, RaQualia deal

Durata said that last December RaQualia granted the company exclusive rights to develop and commercialize dalbavancin in Japan. The second-generation, once-weekly glycopeptide antibiotic is in Phase III testing for acute bacterial skin and skin structure infections (ABSSSI). Financial terms were not disclosed. ...